| Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer |
Cancer and Leukemia Group B |
CALGB-90203 |
| A Prospective Multicenter Registry of Salvage Cryotherapy in Recurrent Prostate Cancer Study |
University of Colorado at Denver and Health Sciences Center |
06-1040 |
| Intermittent Androgen Deprivation in Patients With Stage D2 Prostate Cancer, Phase III |
Southwest Oncology Group |
INT-0162 |
| A Prospective Randomized Phase III, Trial Comparing Consolidation Therapy With or Without Stronium-89 Following Induction Chemotherapy in Androgen-Independent Prostate Cancer |
M.D. Anderson Cancer Center |
NCI-3410 |
| A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone for Selected Patients With Intermediate Risk Prostatic Carcinoma |
Radiation Therapy Oncology Group |
CTSU |
| A Phase I Study of Repetitive Dosing of Anti-CTLA-4 Antibody (MDX-010) in Combination With GM-CSF in Patients With Metastatic, Androgen-Independent Prostate Cancer |
University of California, San Francisco |
NCI-6032 |
| A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men With Prostate Cancer Metastatic to Bone |
Cancer and Leukemia Group B |
CAN-NCIC-PRC2 |
| A Phase II Trial of Docetaxel, Thalidomide, Prednisone and Bevacizumab in Patients With Androgen-Independent Prostate Cancer |
National Cancer Institute (NCI) |
NCI-04-C-0257 |
| Phase I Trial of Concurrent Taxotere With Radiation Therapy and Hormonal Therapy For Clinically Localized High Risk Prostate Cancer |
Medical University of South Carolina |
AVENTIS-MUSC-100783 |
| VELCADE® (Bortezomib) for Injection Therapy for Early Relapsed Prostate Cancer |
Medical University of South Carolina |
MUSC-HR-11357 |
| Docetaxel Plus 6-month Androgen Suppression and Radiation Therapy Versus 6-month Androgen Suppression and Radiation Therapy for Patients With High Risk Localized or Locally Advanced Prostate Cancer: A Randomized Controlled Trial |
Dana-Farber Cancer Institute |
05-043 |
| Phase I/II Trial of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Androgen-Independent Prostate Cancer |
Cytogen Corporation |
424Sm32 |
| The Role of Tomotherapy (Dynamic IMRT and Megavoltage CT Scanning) in Hypofractionated/Dose Escalated Conformal Radiation Treatment Using Magnetic Resonance Spectroscopy (MRS) Scans to Predict and Document the Pattern of Local Failure for High Risk Prostate Cancer |
Alberta Health Services |
GU-06-0052 |
| Improving Assessment (and Ultimately Outcomes) of Permanent Prostate Implant Therapy |
Alberta Health Services |
RIP Project 21694 |
| CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment (CAP) |
Department of Veterans Affairs |
553 |
| Phase III Study of Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients With Advanced Hormone Refractory Prostate Cancer |
Southwest Oncology Group |
SWOG-S0421 |
| A Phase II Study of OGX-011 Given Prior to Radical Prostatectomy in Patients With Localized Prostate Cancer |
University of British Columbia |
R04-0092 |
| A Comparison of 2 Schedules of Meloxicam to Reduce Prostate Swelling in Permanent Seed Prostate Brachytherapy - A Randomized Phase III Trial |
University Health Network, Toronto |
UHN REB 03-0840-C |
| A Randomized Trial of Short Versus Long Acting LHRH Agonist Preparation Prior to Transperineal Implantation of the Prostate |
University of British Columbia |
R03-1213 |
| A Randomized Phase III Study Comparing Androgen Suppression and Elective Pelvic Nodal Irradiation Followed by High Dose 3-D Conformal Boost Versus Androgen Suppression and Elective Pelvic Nodal Irradiation Followed by 125-Iodine Brachytherapy Implant Boost for Patients With Intermediate and High Risk Localized Prostate Cancer |
University of British Columbia |
R04-0050 |
| A Phase I-II Prospective Trial of Conformal Hypofractionated Intensity Modulated Radiotherapy (IMRT) for Localized Adenocarcinoma of the Prostate |
University Health Network, Toronto |
UHN REB 01-0181-C |
| A Phase II Feasibility Study of Cone Beam Computed Tomography for Daily Image Guidance in Patients Receiving Dose Escalated Conformal Radiation Therapy for Prostate Cancer |
University Health Network, Toronto |
UHN REB 05-0037-C |
| A Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Androgen-Independent Prostate Cancer |
Weill Medical College of Cornell University |
0304006100 |
| Phase I/II Trial Examining Dose-per-Fraction Escalation Using Intensity Modulated Radiation Therapy in the Treatment of Prostate Cancer |
University of Wisconsin, Madison |
NCI (P01 CA88960) |
| A Phase II Prostate Cancer Trial Treating Pelvic Lymph Nodes to High Dose Using Intensity Modulated Radiation Therapy |
University of Wisconsin, Madison |
NCI-P01 CA88960 |
| A Phase II Trial of Combination Therapy With Celecoxib and Taxotere for the Treatment of Stage D3 Prostate Cancer |
Department of Veterans Affairs, New Jersey |
GIA16125 |
| A Phase II Trial of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Hormone Resistant Prostate Cancer (HRPC) |
Department of Veterans Affairs, New Jersey |
K-EPIRU-0030-280-US |
| Randomized, Multicentre, Phase III Study in Patients With Intermediate-Risk T1 T2 Prostate Adenocarcinomas, to Verify the Role of Six Months of Total Androgen Blockade for Two Dosage Levels of Prostate Radiation Therapy (70 Gy and 76 Gy) Versus Prostate Radiation Therapy Alone at 76 Gy |
Universitaire de Sherbrooke |
DC-990-0049 |
| Randomized, Multicentre, Phase III Study: Assessment of the Duration of Androgen Blockade Combined With Pelvic Irradiation in High-Risk Prostate Cancers |
Universitaire de Sherbrooke |
DC-990-0056 |
| A Prospective Study of Intermittent Androgen Suppression in Men With Localized Prostate Cancer Who Have Biochemical Relapse After Radiation Therapy or Radical Prostatectomy |
University of Washington |
06-2040-A-02 |
| A Phase I/II Study of Concurrent Weekly Docetaxel (Taxotere®), Androgen Ablation, and Adaptive External Beam Radiotherapy for Localized High-Risk Adenocarcinoma of the Prostate |
UNC Lineberger Comprehensive Cancer Center |
UNC-LCCC-0420 |
| A Phase I Study of Image Guided Dose Escalation With Intensity Modulated Radiation Therapy (IMRT) to Histologically Confirmed Regions of Prostate Cancer |
National Cancer Institute (NCI) |
NCI-P6551 |
| A Pilot Study to Develop a Technique for External Beam Radiotherapy After Radical Prostatectomy Based on MRI-Delineation of the Clinical Target Volume |
University Health Network, Toronto |
UHN REB 04-0759-CE |
| Low Dose Supplemental External Radiation With PD-103 Versus PD-103 Alone For Prostate Cancer |
Schiffler Cancer Center |
04-8-10 |
| A Randomized Trial of Tamsulosin and/or Dutasteride Versus Placebo to Relieve Urinary Symptoms After Brachytherapy for the Treatment of Localized Prostate Cancer |
The Cleveland Clinic |
GSK106046 (formerly 103988) |
| A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer |
The Cleveland Clinic |
Case 8Y04 |
| A Pilot Study of Image Guided Prostate and Pelvic Nodal Irradiation With Intensity Modulated Radiation Therapy (IMRT) in Prostate Cancer |
National Cancer Institute (NCI) |
NCI-P6590 |
| Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer |
Kaiser Permanente |
TK001 |
| Defining the Interaction of Docetaxel and Lonafarnib in Patients With Advanced Malignancies |
Emory University |
EU841-03 |
| Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer |
EDAP TMS S.A. |
G050103 |
| A Randomized Trial of a Shorter Radiation Fractionation Schedule for the Treatment of Localized Prostate Cancer |
Ontario Clinical Oncology Group (OCOG) |
ISRCTN43853433 |
| A Pilot Study of Two Dose Schedules of Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) as Neo-Adjuvant Therapy in Patients With Localized Prostate Cancer |
University of California, San Francisco |
UCSF-H40568-25161-02B |
| Phase II Trial of Thalidomide and Doxil® (Doxorubicin HCL Liposome Injection) in Patients With Androgen Independent Prostate Cancer (AIPC) With a Rising PSA While on Chemotherapy |
University of Pittsburgh |
05-078 |
| CHAARTED: ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer [CHAARTED] |
Eastern Cooperative Oncology Group |
ECOG-E3805 |
| Study of Photodynamic Therapy With WST09 in Patients With Recurrent or Persistent Localized Carcinoma of the Prostate Following Radiation Therapy |
STEBA France |
HEC/WST0512 66N/WST 2.21 |
| A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel |
GPC Biotech |
SAT1-05-09 |
| Feasibility Study for Locally Recurrent Prostate Cancer Treatment Following Radiation Failure With High Intensity Focused Ultrasound (HIFU) |
Lawson Health Research Institute |
11936 |
| Phase I/II Study of Preoperative Radiation and Docetaxel Activity in High Risk Localized Prostate Cancer |
Oregon Health and Science University |
OHSU-SOL-05077-L |
| Randomized Phase III Trial of 3D Conformal Radiotherapy Versus Helical Tomotherapy IMRT in High-Risk Prostate Cancer |
Ottawa Hospital Research Institute |
OTT 05-02 |
| A Phase I Pilot Study of Samarium-153 Combined With Neoadjuvant Hormonal Therapy and Radiation Therapy (IND# 65,173) in Men With Locally Advanced Prostate Cancer |
Thomas Jefferson University |
02C.172 |
| A Phase II Neoadjuvant Trial of Sunitinib Malate (SU011248) Plus Hormonal Ablation for Patients Who Have High Risk Localized Prostate Cancer and Will Undergo Prostatectomy |
M.D. Anderson Cancer Center |
2005-0903 |
| Phase I/II Trial of Epothilone Analog BMS-247550 (Ixabepilone), Mitoxantrone, and Prednisone in Hormone Refractory Prostate Cancer Patients Previously Treated With Chemotherapy |
University of California, San Francisco |
NCI-7347 |
| A Randomized, Double-Blind, Placebo-Controlled Study of The Effects of Pomegranate Extract On Rising Prostate-Specific Antigen Levels In Men Following Primary Therapy |
Roll International Corporation |
UCLA-0507059-01 |
| A Phase II Study to Assess the Feasibility and Activity of Concomitant Radiation and Docetaxel Chemotherapy Followed by Docetaxel Chemotherapy in Prostate Cancer Patients With a Persistent or Rising PSA After Radical Prostatectomy |
University of Texas |
UTHSC-045-0015-377 |
| Pilot Phase II Trial of Bevacizumab in Combination With Hormonal and Radiotherapy in Patients With High-Risk Prostate Cancer |
Benaroya Research Institute |
BRI 3031500 |
| Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy in Addition to Radiosurgery in Patients With One to Three Cerebral Metastases |
North Central Cancer Treatment Group |
ACOSOG-N0574 |
| Randomized Trial of External Beam Radiation With or Without Short-Course Hormonal Therapy in Intermediate Risk Prostate Cancer Patients |
M.D. Anderson Cancer Center |
2003-0819 |
| A Phase II Study of Patupilone (EPO906A) as a Second Line Chemotherapy in Patients With Hormone Refractory Prostate Cancer |
British Columbia Cancer Agency |
OZM-005 |
| Phase I/II Study to Evaluate the Ability of Sorafenib in Overcoming Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer (AIPC) |
Oncology Specialists, S.C. |
0603 |
| Acupuncture Treatment for Hot Flashes in Men With Prostate Cancer, A Phase I/II Study |
New York Methodist Hospital |
NYM # 325 |
| Phase I Study Investigating the Safety and Feasibility of Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-Independent Chemotherapy-Failure Prostate Cancer. |
Oncology Specialists, S.C. |
CST1571BUS260 (0617) |
| A Randomized Controlled Trial Evaluating the Tissue Effects of Preoperative Finasteride Versus Placebo for Patients With Clinically Organ-Confined Prostate Cancer |
M.D. Anderson Cancer Center |
CDR0000531778 |
| A Randomized Comparison of Immediate Versus Deferred Androgen Deprivation Therapy Using Goserelin for Recurrent Prostate Cancer After Radical Radiotherapy. |
Ontario Clinical Oncology Group (OCOG) |
OCOG-P1 |
| A Phase 1 Study of Radiolabeled Monoclonal Antibody 7E11-C5.3(177Lu-meO-DOTA-7E11;CYT-500) in Patients With Progressive Androgen-Independent Prostate Cancer |
Cytogen Corporation |
500Lu01 |
| A Prospective Phase II Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Adenocarcinoma Following External Beam Radiotherapy |
Radiation Therapy Oncology Group |
RTOG-0526 |
| A Randomized Phase II Trial Combining Vaccine Therapy With Prostvac/Tricom and Flutamide, Vs Flutamide Alone in Men With Androgen Insensitive, Non Metastatic (D0.5) Prostate Cancer |
National Cancer Institute (NCI) |
NCI-07-C-0107 |
| A Randomized Phase 2.5 Study of 153Sm-EDTMP (Quadramet) With or Without a PSA/TRICOM Vaccine in Men With Androgen-Insensitive Metastatic Prostate Cancer |
National Cancer Institute (NCI) |
NCI-07-C-0106 |
| The ELDORADO (Eligard®, Docetaxel and Radiotherapy) Study: A Phase II Study of Chemo - Hormonal Therapy and Radiation in High Risk Prostate Cancer |
Nova Scotia Cancer Centre |
DOCET-L-01892 |
| A Randomized, Phase II Study of GW786034 (Pazopanib) in Stage D0 Relapsed Androgen Sensitive Prostate Cancer Following Limited GnRH Agonist Therapy |
University of Chicago |
UCCRC-14954A |
| Phase I/II Study of Docetaxel (Taxotere) in Combination With Doxorubicin HCI Liposome Injection (Doxil) in Advanced Androgen-Independent Prostate Cancer (AIPC) |
James Graham Brown Cancer Center |
IRB# 575-03 |
| Prostate Cancer Prevention by n-3 Unsaturated Fatty Acids |
Dana-Farber Cancer Institute |
DFCI-03116 |
| Phase Ib Study of Polyphenon E in a Pre-Prostatectomy Prostate Cancer Cohort |
University of Arizona |
UARIZ-HSC-06-0695-04 |
| A Phase II Study of Sorafenib (Nexavar®) Prior to Radical Prostatectomy in Patients With High-Risk Localized Prostate Cancer |
Fred Hutchinson Cancer Research Center |
BAYER-FHCRC-6307 |
| Phase II Trial of Avastin (Bevacizumab) in PSA Relapse Androgen Independent Prostate Cancer |
Barbara Ann Karmanos Cancer Institute |
GENENTECH-0703004652 |
| A Phase II Study of Ara-C (Cytarabine) in Men With Androgen Independent Prostate Cancer |
University Health Network, Toronto |
SLAP41206 |
| Salvage Radiation Therapy and Docetaxel (Taxotere) for Biochemical Failure After Radical Prostatectomy |
University of Michigan Cancer Center |
UMCC 2006.066 |
| I-125 Versus Pd-103 for Medium Risk Prostate Cancer |
Puget Sound Veterans Administration Health Care System |
02-4407-V04 |
| A Phase II Study of GW786034 (Pazopanib) With or Without Bicalutamide in Hormone Refractory Prostate Cancer |
Princess Margaret Hospital, Canada |
PMH-10036920 |
| A Randomized Phase II Study of Intermittent Chemotherapy or Intermittent Chemotherapy With Maintenance GM-CSF in Patients With Previously Untreated Hormone Refractory Prostate Cancer |
University of California, San Francisco |
UCSF055511 |
| A Phase III Study of Active Surveillance Therapy Against Radical Treatment in Patients Diagnosed With Favourable Risk Prostate Cancer [START] |
NCIC Clinical Trials Group |
SWOG-PR11 |
| Phase II Trial of Vitamin D and Soy Supplementation for Biochemically Recurrent Prostate Cancer Following Definitive Local Therapy |
Wake Forest University |
CCCWFU-IRB00000371 |
| Phase II Study of Carboplatin Plus Docetaxel (Taxotere) in Patients With Anaplastic Prostate Carcinoma |
M.D. Anderson Cancer Center |
2006-0097 |
| A Randomized, Open Label, Multicenter, Phase III, 2-Arm Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Subjects With a Rising PSA Following Definitive Local Therapy |
Sanofi-Aventis |
EudraCT#:2007-000323-17 |
| A Randomized, Double Blind, Placebo-Controlled Phase II Study of Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer |
University of Chicago |
15393B |
| Multicentre, Double-Blind Study Comparing 0.5mg Dutasteride vs. Placebo Daily in Men Receiving Intermittent Androgen Ablation Therapy for Prostate Cancer |
Fred Hutchinson Cancer Research Center |
UWCC- 06-4211-H/B |
| Study of Serum 25(OH) D3 Level Variability in Response to Different Doses of Oral Vitamin D Supplementation in Prostate Cancer Patients |
Roswell Park Cancer Institute |
RPCI-I-95406 |
| Transperineal Interstitial Permanent Brachytherapy Alone for Selected Patients With Intermediate Risk Prostatic Carcinoma |
M.D. Anderson Cancer Center |
2006-0038 |
| A Randomized, Phase II Trial of AZD2171, Docetaxel, and Prednisone Compared to Docetaxel and Prednisone in Patients With Metastatic, Hormone Refractory Prostate Cancer |
Barbara Ann Karmanos Cancer Institute |
WSU-2007-015 |
| Adjuvant 3DCRT/IMRT in Combination With Androgen Suppression and Docetaxel for High Risk Prostate Cancer Patients Post-Prostatectomy: A Phase II Trial |
Radiation Therapy Oncology Group |
RTOG-0621 |
| A Phase I/II Study of Oral Calcitriol in Combination With Ketoconazole in Androgen Independent Prostate Cancer |
Roswell Park Cancer Institute |
RPCI-I-68905 |
| Radioimmunotherapy Phase I Dose-Escalation Studies in Prostate Cancer Using 177Lu-J591 Antibody: Dose Fractionation Regimen |
Weill Medical College of Cornell University |
Repetitive dosing 177Lu-J591 |
| An Observational Study of Continuous Oral Dosing of an Irreversible CYP17 Inhibitor, Abiraterone, in Castration Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma |
Cougar Biotechnology, Inc. |
COU-AA BMA |
| Androgen Deprivation and Localized Radiotherapy to Metastases in Patients With Oligometastatic Hormone - Sensitive Prostate Cancer |
Beckman Research Institute |
CHNMC-05190 |
| A Phase I and II Study of Stereotactic Body Radiation Therapy (SBRT) for Low and Intermediate Risk Prostate Cancer (SBRT Prostate) |
Simmons Cancer Center |
UMN-2006UC048 |
| A Phase II Trial of Samarium 153 Followed by Salvage Prostatic Fossa 3DCRT or IMRT Irradiation in High-Risk, Clinically Non-Metastatic Prostate Cancer After Radical Prostatectomy |
Radiation Therapy Oncology Group |
RTOG-0622 |
| Phase 2 Trial of Maximum Androgen Blockade (MAB) Dose Escalation From 50 mg to 150 mg Bicalutamide (Casodex) for Biochemical Failure in Prostate Cancer Patients |
Canadian Urology Research Consortium |
D6876L00008 |
| A Phase II Trial of Phenoxodiol in Patients With Castrate and Non-Castrate Prostate Cancer |
Marshall Edwards Pty Limited |
Yale 0703002467 |
| A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy |
Radiation Therapy Oncology Group |
RTOG-0534 |
| A Phase 1/2, Open-Label, Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects |
Millennium Pharmaceuticals, Inc. |
TAK-700-201 |
| BMS CA180-097: A Phase II Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer, Previously Treated With Chemotherapy |
University of California, Irvine |
BMS CA180-097 |
| A Pilot Study of High Dose Rate Brachytherapy as Definitive Management for Intermediate Risk Prostate Cancer |
Memorial Sloan-Kettering Cancer Center |
MSKCC-07120 |
| Phase Ib/II Evaluation of RAD001 With Docetaxel and Bevacizumab in Patients With Metastatic Androgen Independent Prostate Cancer |
Cedars-Sinai Medical Center |
CRAD001CUS2468 |
| Assessment of the Functional Significance of Accessory Pudendal Arteries |
Memorial Sloan-Kettering Cancer Center |
06-073 |
| Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer |
University of Iowa |
PC061667/2 |
| A Randomized, Controlled Trial of Replication-Competent Adenovirus-Mediated Suicide Gene Therapy in Combination With IMRT Versus IMRT Alone for the Treatment of Newly-Diagnosed Prostate Cancer With an Intermediate Risk Profile |
Henry Ford Health System |
P01 CA098012 |
| Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy |
University of Iowa |
PC061667/1 |
| A Phase II Study of Sorafenib in Combination With Docetaxel in Patients With Androgen-Independent Prostate Cancer |
University of Pennsylvania |
SANOFI-AVENTIS-UPCC-03806 |
| Neoadjuvant Androgen Depletion in Combination With Vorinostat Followed by Radical Prostatectomy for Localized Prostate Cancer: Total Androgen-Receptor Gene Expression Targeted Therapy (TARGET) |
Memorial Sloan-Kettering Cancer Center |
MSKCC IRB 06-160 |
| A Prospective Trial of Soy Derivatives for Control of Hot Flashes in Men on Androgen Deprivation Therapy |
University of Kansas |
9639 |
| Pilot Phase II Study to Determine the Effects of Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate in Patients Who Are Scheduled for Radical Prostatectomy With Genomic Correlates of Pathological Response |
University of California, Irvine |
UCI 07-14 |
| Pilot Study of High Dose Rate Prostate Brachytherapy as Salvage for Locally Recurrent Prostate Cancer Previously Treated With External Beam Radiotherapy |
Memorial Sloan-Kettering Cancer Center |
06-122 |
| Immunotherapy of Patients With Androgen-Independent Prostate Carcinoma Using NY-ESO-1/LAGE1 Peptide Vaccine (SPORE #: 11-01-30-14) |
Baylor College of Medicine |
BCM-SPORE-11-01-30-14 |
| A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 10 mg ZD4054 in Combination With Docetaxel in Comparison With Docetaxel in Patients With Metastatic Hormone-resistant Prostate Cancer |
AstraZeneca |
D4320C00033 |
| Prospective Evaluation of Cyberknife Stereotactic Radiosurgery for Low and Low/Intermediate Risk Prostate Cancer |
Case Comprehensive Cancer Center |
CASE-13807 |
| A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients |
AstraZeneca |
D4320C00015 |
| A Phase II Trial of RAD001 and Bicalutamide for Androgen Independent Prostate Cancer |
Dana-Farber Cancer Institute |
07-316 |
| Sunitinib, Hormonal Ablation and External Beam Radiation Therapy for High-Risk and Locally Advanced Prostate Cancer |
M.D. Anderson Cancer Center |
2006-0684 |
| Phase II Trial of Zemplar (19-nor-1 a,25-Dihydroxyvitamin D2, Paricalcitol Capsule) on Bony Remodeling in Advanced Androgen-Insensitive Prostate Cancer |
Wake Forest University |
CCCWFU-85107 |
| A Phase II Study of Satraplatin and Prednisone in Metastatic Androgen Independent Prostate Cancer (AIPC) |
National Cancer Institute (NCI) |
NCI-P07140 |
| A Randomized Phase 2 Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Hormone Refractory Prostate Cancer |
Eli Lilly and Company |
H8Z-MC-JACR |
| Prospective Evaluation of CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry |
Accuray Incorporated |
ACCP002.1 |
| Prospective Evaluation of CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer: Homogenous Dose Distribution |
Accuray Incorporated |
ACCP001.2 |
| A Phase III Study of Neoadjuvant Docetaxel and Androgen Suppression Plus Radiation Therapy Versus Androgen Suppression Alone Plus Radiation Therapy for High-Risk Localized Adenocarcinoma of the Prostate (DART) |
NCIC Clinical Trials Group |
CAN-NCIC-PR12 |
| A Phase II Study Evaluating the Toxicity and Efficacy of Single Agent Lenalidomide (Revlimid®) in Chemotherapy-Naïve Androgen-Independent Prostate Cancer Patients |
Oncology Specialists, S.C. |
RV-PCA-PI-327 |
| A Phase II Trial of Avastin, Docetaxel and Androgen Deprivation Followed by Continued Avastin and Androgen Deprivation for Men With a Rising PSA After Local Therapy |
Dana-Farber Cancer Institute |
08-004 |
| An Open Label, Single Arm, Phase Ib Dose Finding Study of i.v. Panobinostat (LBH589) With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer |
Novartis Pharmaceuticals |
EUDRACT # = 2007-003315-30 |
| Phase Ia/Ib Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning |
Roger Williams Medical Center |
W81XWH-05-1-0408 |
| A Phase II Study of AT101 to Abrogate BCL-2 Mediated Resistance to Androgen Ablation Therapy in Patients With Newly Diagnosed Stage D2 Prostate Cancer |
Cancer Institute of New Jersey |
CINJ-0220080008 |
| A Phase III Intensity Radiotherapy Dose Escalation for Prostate Cancer Using Hypofractionation |
M.D. Anderson Cancer Center |
ID00-381 |
| Effect of Dutasteride on Androgen-Response Gene Expression During the Tumor Regrowth Phase of Intermittent Androgen Ablation Therapy in Patients With Advanced Prostate Cancer |
NorthShore University HealthSystem Research Institute |
EH07-109 |
| A Phase I/II Trial of Adjuvant 3-D Conformal Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic T2-T3N0M0 Prostate Cancer |
USC/Norris Comprehensive Cancer Center |
4P-06-3 |
| A Phase II Trial of a Combination Herbal Therapy for Men With Biochemical Recurrence of Prostate Cancer After Initial Local Therapy |
USC/Norris Comprehensive Cancer Center |
4P-07-3 |
| Randomized, Controlled Phase II Study of Valproic Acid in Patients With Non-metastatic Biochemical Progression of Prostate Cancer |
Sidney Kimmel Comprehensive Cancer Center |
JHOC-NA_00010227 |
| A Multicenter, Randomized, Double-Blind, Phase 3 Study Of Sunitinib Plus Prednisone Versus Prednisone In Patients With Progressive Metastatic Hormone-Refractory Prostate Cancer After Failure Of A Docetaxel-Based Chemotherapy Regimen |
Pfizer |
A6181120 |
| A Phase II Pharmacokinetic and Efficacy Study of Nordihydroguaiaretic Acid (NDGA) in Non-Metastatic Recurrent Prostate Cancer |
University of California, San Francisco |
075511 |
| A Phase II Randomized, Open-Label, Three-Arm Study of Green Tea, Black Tea and a Water Control in Men Scheduled for Prostatectomy |
Jonsson Comprehensive Cancer Center |
UCLA-061109702 |
| A Phase II Study of Hypofractionated Image Guided Proton Radiation Therapy for Low and Intermediate Risk Adenocarcinoma of the Prostate |
University of Florida |
UFPTI 0702-PR04 |
| Pilot Immunotherapy Study of Combination PSMA and TARP Peptide With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment |
H. Lee Moffitt Cancer Center and Research Institute |
USFIRB #106346 |
| A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men With Prostate Cancer Metastatic to Bone |
University of Medicine and Dentistry New Jersey |
0120070271 |
| Phase I Dose Escalation Trial of CP-675,206 (Tremelimumab, Anti-CTLA-4 Monoclonal Antibody) in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer |
University of Wisconsin, Madison |
CO07808 |
| Immunotherapy of Patients With Androgen-Independent Prostate Carcinoma Using NY-ESO-1/LAGE1 Peptide Vaccine (SPORE #: 11-01-30-14) |
Baylor College of Medicine |
P50-CA58204 |
| Pilot Evaluation of High Dose-Rate Brachytherapy ± Image-Guided Intensity Modulated Hypofractionated External Radiotherapy for Localized Prostate Cancer |
Mayo Clinic |
MAYO-MC0652 |
| A Randomized, Multicenter, Single Blind Study in Men With Metastatic Androgen Independent Prostate Cancer to Evaluate Sipuleucel-T Manufactured With Different Concentrations of PA2024 Antigen |
Dendreon |
P07-2 |
| A Single Center, Open Label, Phase 2 Trial of Immunotherapy With Sipuleucel-T as Neoadjuvant Treatment in Men With Localized Prostate Cancer |
Dendreon |
P07-1 |
| A Phase I/II, Open-Label, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Potential Activity of HE3235 When Administered Orally to Patients With Prostate Cancer |
Hollis-Eden Pharmaceuticals |
HE3235-0201 |
| NJ 1808: Autophagic Cell Death in Patients With Hormone-Dependent Prostate-Specific Antigen Progression After Local Therapy for Prostate Cancer |
Cancer Institute of New Jersey |
CINJ-080803 |
| An Open-Label Extension Study of the Effects of Pomegranate Extract on Rising Prostate-Specific Antigen Levels in Men Following Primary Therapy for Prostate Cancer. |
Radiant Research |
GUP-0205-1X |
| Multimodality Therapy for Recurrent High Risk Prostate Cancer: A Phase II Study |
Duke University |
10747 |
| A Randomized, Double Blind, Placebo Controlled Clinical Trial of L-SeMet Supplementation and Finasteride Treatment of Patients With Prostate Cancer Prior to Robotic Prostatectomy/Brachytherapy |
Roswell Park Cancer Institute |
RPCI-I-104607 |
| Randomized Trial of the Effects of Vitamin D on Prostate Cancer-Associated Lesions and on Vitamin D Metabolites in Prostate |
University of Toronto |
M2140 |
| A Randomized Double-Blind Phase III Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer |
Bristol-Myers Squibb |
CA180-227 |
| The Impact of Antioxidants on MRI Markers of Cell Proliferation and Hypoxia Among Men on Active Surveillance With Early Stage Prostate Cancer |
University Health Network, Toronto |
07-0580-B |
| A Phase 1 Study of MK4827 in Patients With Advanced Solid Tumors |
Merck |
MK4827-001 |
| Phase II Chemoprevention Trial of Selenium and Prostate Cancer (Watchful Waiting With Selenium Trial) |
University of Arizona |
97-0395-01 |
| A Phase II Randomised Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer. |
British Columbia Cancer Agency |
OZM-011 |
| Randomized Placebo-Controlled Adjuvant Study of Prevention of Prostate Cancer Recurrence After Radical Prostatectomy by Soy Protein Isolate |
University of Illinois |
UIC-2006-0706 |
| Phase II Study of Neoadjuvant IMC-A12 Combined With Androgen Deprivation Prior to Prostatectomy |
Fred Hutchinson Cancer Research Center |
35550-H |
| Phase I-II Trial of Genistein in Subjects Receiving Palliative External Beam Radiation Therapy for Osseous Metastases: A Study of Palliation of Symptoms and Quality of Life |
Masonic Cancer Center, University of Minnesota |
UMN-0803M29541 |
| A Multicenter Clinical Study of the Sonablate® 500 (SB-500) for the Treatment of Localized (T1c/T2a) Prostate Cancer With HIFU |
USHIFU, LLC |
FSI-002 |
| A Phase 1b/2 Study to Assess the Safety and Efficacy of AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer |
Amgen |
20070611 |
| A Multicenter Clinical Study of the Sonablate® 500 (SB-500) for the Treatment of Locally Recurrent Prostate Cancer With HIFU |
USHIFU, LLC |
FSI-003 |
| A Phase II Study of Focal Cryoablation in Low-Risk Prostate Cancer |
Memorial Sloan-Kettering Cancer Center |
08-118 |
| Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy |
Dana-Farber Cancer Institute |
08-190 |
| A Phase II Randomized, Placebo Controlled Clinical Trial to Study the Efficacy and Safety of Bicalutamide With or Without Deforolimus (Ridaforolimus) in Men With Asymptomatic, Metastatic Castrate-resistant Prostate Cancer |
Merck |
MK8669-002 |
| A Phase Ib of Mushroom Powder in Biochemically Recurrent, Hormone Naive Prostate Cancer |
Beckman Research Institute |
CHNMC-08012 |
| A Phase II Study of Docetaxel and Modulation of Autophagy With Hydroxychloroquine for Metastatic Hormone Refractory Prostate Cancer |
Cancer Institute of New Jersey |
0220080244 |
| Phase I Trial of In Situ Gene Therapy for Locally Recurrent Prostate Cancer Following Radiation Therapy Failure Using Sodium/Iodide Symporter and Radioiodine |
Mayo Clinic |
MAYO-MC0252 |
| Fiducial Localization and Individualized Radiotherapy in Prostate Cancer (FLIP) |
University Health Network, Toronto |
UHN REB 08-0271-C |
| A Phase I Dose Escalating Study Evaluating the Pharmacodynamic Profile and Safety of BN83495 in Patients With Prostate Cancer With Evidence of Disease Progression While on Androgen Ablative Therapy |
Ipsen |
X-52-58064-003 |
| Phase I, Open Label, Single Center, Multiple Dose, Dose Escalation Clinical Study of SU011248 in Subjects With High Risk Prostate Cancer Who Have Elected to Undergo Radical Prostatectomy |
University of California, Los Angeles |
Pfizer2005-0958 |
| Salvage Prostatectomy After Radiotherapy: Whole-Mount Histopathological Validation for Tumor-Targeted Salvage HDR Brachytherapy |
University Health Network, Toronto |
NIH CA12156 |
| A Dose-escalation Study Using a Maximal Simultaneous Intraprostatic Boost With RapidArc Intensity Modulated Radiotherapy in Intermediate Risk Prostate Cancer |
British Columbia Cancer Agency |
IMAX |
| Randomized, Double-Blind, Placebo-Controlled Trial Assessing The Efficacy And Safety Of Dutasteride At Improving Lower Urinary Tract Symptoms In Men With Clinically Localized Prostate Cancer Being Treated With Single-Dose Goserelin, Trans-Urethral Incision Of Prostate, And Interval Brachytherapy |
Bay State Clinical Trials, Inc. |
047838 |
| A Phase III Biomarker Study of Neoadjuvant Vitamin E in Patients With Locally Treatable Prostate Cancer Prior to Prostatectomy or Brachytherapy |
New Mexico Cancer Care Alliance |
INST 0808 |
| Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate |
Sidney Kimmel Comprehensive Cancer Center |
NA_00019393 |
| Randomized Phase II Trial of Bicalutamide +/- RAD001 in Patients With Hormone-Independent Prostatic Adenocarcinoma (HIPC) After the First-Line Androgen Deprivation Therapy |
University of California, Davis |
NOVARTIS-UCDCC-215 |
| Telephone Counseling: Men With Prostate Cancer & Partners |
University of Arizona |
R21CA113409 |
| BrUOG-PROS-221 Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer: A Phase II Study |
Brown University |
BMS-CA163-164 |
| Phase II Open-Label Safety Extension Study Of Tanezumab In Cancer Patients With Pain Due To Bone Metastases |
Pfizer |
A4091029 |
| Phase I-II Trial of Hypofractionated Conformal Proton Beam Radiation Therapy for Favorable-Risk Prostate Cancer |
Loma Linda University |
58116 |
| A Pilot Study of Exercise in Men With Prostate Cancer Receiving Androgen Depletion Therapy |
University of Manitoba |
H2008:035 |
| Low-Fat Diet and Omega-Fatty Acids for Prostate Cancer Prevention |
University of California, Los Angeles |
P50CA092131-01A1 |
| A Randomized, Double-Blind Study of Combination Vitamin E, Selenium and Lycopene vs. Placebo in Men Undergoing Radical Prostatectomy for Prostate Cancer |
University Health Network, Toronto |
08-0604-CE |
| A Pilot Randomized Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) in Patients With Non-Metastatic Castrate-Resistant Prostate Cancer |
University of Wisconsin, Madison |
CO08802 |
| VIRTUAL HDR CYBERKNIFE RADIOSURGERY FOR LOCALLY RECURRENT PROSTATIC CARCINOMA: A PHASE II STUDY |
CyberKnife Centers of San Diego |
CK Recurrent Prostate SD |
| Efficacy of Exercise in Promotion Cognitive-psychosocial Functions in Men With Prostate Cancer Receiving Androgen Depletion Therapy |
University of Manitoba |
H2008:318 |
| A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy |
Weill Medical College of Cornell University |
J591+Ketoconazole |
| A Phase II Study of Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer |
Hoosier Oncology Group |
HOG GU07-124 |
| A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel |
Bristol-Myers Squibb |
2008-003314-97 |
| A Phase I/II, Non-randomized, Multiple Dose, Dose Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Therapeutic Vaccine, BP-GMAX-CD1, Plus Activating Agent, AP1903, in Patients With Androgen-independent Prostate Cancer |
Bellicum Pharmaceuticals |
BP-PC-001 |
| A Limited, First-in-Man, Phase IB Evaluation of BMTP-11 in Patients With Castrate-Resistant Prostate Cancer With High-Volume Osseous Metastases and no Standard Treatment Options |
M.D. Anderson Cancer Center |
2008-0395 |
| Regional Cryoablation for Localized Adenocarcinoma of the Prostate |
M.D. Anderson Cancer Center |
2008-0244 |
| Phase I/II Randomized Trial of LBH589 (Panobinostat) at Two Dose Levels Combined With Bicalutamide (Casodex) in Men With Castration-Resistant Prostate Cancer |
New York University School of Medicine |
NYU 08-479 |
| A Pilot Phase II Study to Determine the Effects of Taxotere Plus Sunitinib on Newly Diagnosed, Hormone Refractory, Symptomatic and Asymptomatic, Metastatic Prostate Cancer Who Are Chemotherapy-naïve. |
University of California, Irvine |
HS#:2008-6187 |
| A Phase II, Open Label Assessment of Neoadjuvant Intervention With Metformin Against Tumour Expression of Signaling |
University Health Network, Toronto |
PMH-ANIMATE-001 |
| A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer |
Cougar Biotechnology, Inc. |
COU-AA-302 |
| Randomized Placebo-Controlled, Double-Blind Study of Cholecalciferol Replacement in Patients on Expectant Management for Localized Prostate Cancer |
Roswell Park Cancer Institute |
RPCI-I-128308 |
| A Randomized Phase II Clinical Trial of Two Dose-levels of Itraconazole in Patients With Metastatic Castration-resistant Prostate Cancer |
Johns Hopkins University |
JHMI-IRB number: NA_00027099 |
| Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer |
Duke University |
00016256 |
| Phase II Trial of B-DIM (DIM: 3,3 Diindolylmethane) on Intermediate Endpoint Biomarkers in Patients With Prostate Cancer Who Are Undergoing Prostatectomy |
Barbara Ann Karmanos Cancer Institute |
WSU-2007-128 |
| Performance Evaluation of the AMS CONTINUUM™ Device in Facilitating Vesico-Urethral Anastomosis Following a Radical Prostatectomy |
American Medical Systems |
G090011 |
| An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer |
Dendreon |
P09-1 |
| Phase I/IIa Study of RNActive®-Derived Therapeutic Vaccine in Advanced or Metastatic Hormone Refractory Prostate Cancer |
University of Florida |
CV-9103-002 |
| A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer |
National Cancer Institute (NCI) |
NCI-P08397 |
| MRI-Guided HDR Brachytherapy for Prostate Cancer |
University Health Network, Toronto |
UHN REB 09-0026-C |
| A Phase II Trial of Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer |
Duke University |
CA180-263 |
| Phase II Study Investigating the Toxicity and Efficacy of Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients |
Oncology Specialists, S.C. |
OSRI 0901 |
| A Phase 2 Open-Label, Randomized, Multi-center Study of Neoadjuvant Abiraterone Acetate (CB7630) Plus Leuprolide Acetate and Prednisone Versus Leuprolide Acetate Alone in Men With Localized High Risk Prostate Cancer |
Cougar Biotechnology, Inc. |
COU-AA-201 |
| Phase I/II Study of Sorafenib Concurrent With Androgen Deprivation and Radiotherapy in the Treatment of Intermediate- and High-Risk Localized Prostate Cancer |
Beth Israel Medical Center |
SR06-959 |
| A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment |
Ferring Pharmaceuticals |
RISPSA |
| A Randomized Trial of Modifications to Radical Prostatectomy: Feasibility Study |
Memorial Sloan-Kettering Cancer Center |
09-051 |
| A Modular Phase I-II Trial of Lenalidomide and Paclitaxel in Men With Castration-Resistant Prostate Cancer and Lymph-Node Dominant Metastases |
M.D. Anderson Cancer Center |
2008-0606 |
| A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer |
Radiation Therapy Oncology Group |
RTOG-0815 |
| Phase II Trial of Temporary Androgen Deprivation Therapy in High Risk Prostate Cancer Following Radical Prostatectomy |
Mayo Clinic |
MC0852 |
| Phase I/II Study of Lenalidomide (RevlimidTM ) and GM-CSF in Androgen Independent Prostate Cancer |
The Cleveland Clinic |
BAYER-CASE-3805 |
| A Phase II Study of Stereotactic Body Radiotherapy (SBRT) for Prostate Cancer Using Continuous Real-time Evaluation of Prostate Motion and IMRT Plan Reoptimization Based on the Anatomy of the Day |
Duke University |
Pro00018266 |
| A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer |
National Cancer Institute (NCI) |
09-C-0195 |
| A Study of Pazopanib as Second Line Therapy in Patients With Prostate Cancer Refractory to Total Androgen Blockade. |
Illinois CancerCare, P.C. |
ICC #1 |
| A Prospective, Multicenter Phase I/II Safety and Tolerability Study of Unilateral Vascular-Targeted Photodynamic Therapy Using WST11 in Patients With Localized Prostate Cancer |
Steba Biotech S.A. |
CLIN901 PCM202 |
| An Open-Label, Multi-Centre, Randomised, Parallel-Arm One-Year Trial, Comparing the Efficacy and Safety of Degarelix Three-Month Dosing Regimen With Goserelin Acetate in Patients With Prostate Cancer Requiring Androgen Deprivation Therapy |
Ferring Pharmaceuticals |
FE200486 CS35 |
| Transrectal Ultrasound (TRUS) Imaging of the Prostate Gland and Neurovascular Bundles (NVB) During Robot-Assisted Laparoscopic Radical Prostatectomy (RALRP) |
Johns Hopkins University |
NA_00014120 |
| Vitamin D Supplementation in Veterans With Early-Stage Prostate Cancer |
Department of Veterans Affairs |
CLIN-004-09S |
| A Phase I/II Trial of Ketoconazole, Hydrocortisone, Dutasteride and Lapatanib (KHAD-L) in Castration Resistant Prostate Cancer With Pre- and Post-therapy Tumor Biopsies |
Beth Israel Deaconess Medical Center |
08-374 |
| Ultrasound-Guided Navigation in Robot-Assisted Laparoscopic Radical Prostatectomy |
Johns Hopkins University |
NA_00027540 |
| ARMOR1: Phase 1/2, Open Label, Dose Escalation, Selected Dose Comparison Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer |
Tokai Pharmaceuticals |
TOK-200-05 |
| Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy |
University of Florida |
UFPTI 0902-PR06 |
| Phase 1 Study of Stereotactic Hypofractionated Radiosurgery of Low Grade Prostate Cancer/Early Stage |
San Diego Radiosurgery |
SDRS0001 |
| AFFIRM: A Multinational Phase 3, Randomized, Double-Blind, Placebo-COntrolled Efficacy and Safety Study of Oral MDV3100 in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy |
Medivation, Inc. |
CRPC2 |
| Does Postoperative Gabapentin Reduce Pain, Opioid Consumption & Anxiety & Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy? |
Sunnybrook Health Sciences Centre |
075-2005 |
| A Randomized Placebo-Controlled Double-Blind Clinical Trial to Assess the Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate Cancer |
University of Colorado, Denver |
COMIRB#: 09-0247 |
| A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or WITHOUT LENALIDOMIDE in Subjects With Castrate-Resistant Prostate Cancer |
Celgene Corporation |
EudraCT Number 2008-007969-23 |
| An Open-label, Multicenter, Phase 2 Study of Single-agent CNTO 888 (an Anti-CCL2 Monoclonal Antibody) for the Treatment of Patients With Metastatic Castrate-Resistant Prostate Cancer |
Centocor, Inc. |
2009-011251-48 |
| A Phase I/II Study of Bevacizumab and Erlotinib in Combination With Docetaxel and Prednisone for Patients With Hormone Refractory Prostate Cancer |
Columbia University |
AAAB8399 |
| Biomarkers of Prostate and Cardiovascular Health of Men Undergoing Prostatectomy Consuming Different Amounts of Soy-Tomato Juice |
Arthur G. James Cancer Hospital & Richard J. Solove Research Institute |
OSU-2007C0026 |
| Temsirolimus, an mTOR Inhibitor, to Reverse Androgen Insensitivity in Patients With Castration-resistant Prostate Cancer |
Stanford University |
PROS0028 |
| Phase I/II Trial of Anti-IGF-IR Monoclonal Antibody IMC-A12 Plus mTOR Inhibitor Temsirolimus (CCI-779) in Metastatic Castration- Resistant Prostate Cancer (CRPC) |
Memorial Sloan-Kettering Cancer Center |
IRB #09-117 |
| A Prospective Study Implementing MRI Based Treatment Planning for Clinical Target Volume Definition and Immobilization in Post-Prostatectomy Radiation Treatment |
Abramson Cancer Center of the University of Pennsylvania |
NCI-2009-01441 |
| Phase II Clinical Trial of Purified Isoflavones in Prostate Cancer: Comparing Safety, Effectiveness and Mechanism of Action Between African American and Caucasian Men |
H. Lee Moffitt Cancer Center and Research Institute |
1P20MD003375-01 |
| An Endocrinologically and Pharmacologically Directed Trial of Ketoconazole and Corticosteroids in Castration Resistant Prostate Cancer |
University of California, San Francisco |
CC # 09553 |
| A Phase II Study of Proton-Based Radiation Therapy With Elective Pelvic Nodal Irradiation, Concomitant Docetaxel, and Adjuvant Androgen Deprivation for High-Risk Prostate Adenocarcinoma |
University of Florida |
UFPTI 0703 - PR05 |
| A Phase I Dose-Escalation Study of Preoperative Radiation Therapy Followed by Radical Prostatectomy in Patients With High Risk, Localized Carcinoma of the Prostate |
Duke University |
00006510 |
| Vitamin D and Prostate Cancer |
Medical University of South Carolina |
MUSC GCRC #790 |
| A Feasibility Trial of Proton Radiation Therapt Using Standard Fractionation for Low-Risk Adenocarcinoma of the Prostate |
Abramson Cancer Center of the University of Pennsylvania |
NCI-2009-01500 |
| Pilot Trial to Evaluate the Safety and Efficacy of the Administration of Bicalutamide (Casodex TM) Per Day in Combination With Raloxifene (Evista TM) Per Day in Patients With Hormone Refractory Prostate Cancer |
Mayo Clinic |
NCI-2009-01700 |
| Hypo-fractionated Stereotactic Body Radiotherapy for Localized Prostate Cancer |
University of California, Los Angeles |
09-10-081 |
| A Phase II, Open-Label, Single-Arm Study Evaluating the Safety, Efficacy and Pharmacokinetics of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Had Prior Chemotherapy |
Kinex Pharmaceuticals, LLC |
KXO1-002-09 |
| A Phase II Study of SB939 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer |
NCIC Clinical Trials Group |
CAN-NCIC-IND195 |
